ArticleThe American journal of pathology2000
Loss of FHIT expression in transitional cell carcinoma of the urinary bladder.
Article in The American journal of pathology, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 66 citations in OpenAlex.
- The ubiquitous 'cancer mutational signature' 5 occurs specifically in cancers with deletedOncotarget · 2017Article
- Identification of a Novel UT-B Urea Transporter in Human Urothelial Cancer.Frontiers in physiology · 2017Article
- Biomarkers for bladder cancer management: present and future.American journal of clinical and experimental urology · 2014Review
- Aberrant crypt focus and fragile histidine triad protein in sporadic colorectal carcinoma.World journal of gastrointestinal oncology · 2012Article
- Common fragile site tumor suppressor genes and corresponding mouse models of cancer.Journal of biomedicine & biotechnology · 2011Review
- Oncosuppressor proteins of fragile sites are reduced in cervical cancer.Cancer letters · 2010Article
- Fragile histidine triad protein: structure, function, and its association with tumorogenesis.Journal of cancer research and clinical oncology · 2010Review
- Targeted therapies in the management of metastatic bladder cancer.Biologics : targets & therapy · 2007Article
- Association of KLK5 overexpression with invasiveness of urinary bladder carcinoma cells.Cancer science · 2007Article
- Fragile genes as biomarkers: epigenetic control of WWOX and FHIT in lung, breast and bladder cancer.Oncogene · 2005Article
- The apoptotic pathway triggered by the Fhit protein in lung cancer cell lines is not affected by Bcl-2 or Bcl-x(L) overexpression.Oncogene · 2004Article
- Collecting duct carcinoma of the kidney: an immunohistochemical study of 11 cases.BMC urology · 2004Article
- CpG methylation in the Fhit regulatory region: relation to Fhit expression in murine tumors.Oncogene · 2004Article
- Reduced Fhit protein expression in human malignant mesothelioma.Virchows Archiv : an international journal of pathology · 2004Article
- Restoration of fragile histidine triad (FHIT) expression induces apoptosis and suppresses tumorigenicity in lung and cervical cancer cell lines.Proceedings of the National Academy of Sciences of the United States of America · 2002Article
- Sequence conservation at human and mouse orthologous common fragile regions, FRA3B/FHIT and Fra14A2/Fhit.Proceedings of the National Academy of Sciences of the United States of America · 2001Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 3 institutions in 2 countries.
Funding
Abstract
Cytogenetic and loss of heterozygosity (LOH) studies demonstrated chromosome 3p deletions in transitional cell carcinoma (TCC). We recently cloned the tumor suppressor gene FHIT (fragile histidine triad) at 3p14.2, one of the most frequently deleted chromosomal regions in TCC of the bladder, and showed that it is the target of environmental carcinogens. Abnormalities at the FHIT locus have been found in tumors of the lung, breast, cervix, head and neck, stomach, pancreas, and clear cell carcinoma of the kidney. We examined six TCC derived cell lines (SW780, T24, Hs228T, CRL7930, CRL7833, and HTB9) and 30 primary TCC of the bladder for the integrity of the FHIT transcript, using reverse transcriptase-polymerase chain reaction (RT-PCR) to investigate a potential role of the FHIT gene in TCC of the bladder. In addition, we tested expression of the Fhit protein in the six TCC-derived cell lines by Western blot analysis and in 85 specimens of primary TCCs by immunohistochemistry. Three of the six cell lines (50%) did not show the wild-type FHIT transcript, and Fhit protein was not detected in four of the six cell lines (67%) tested. Fhit expression also was correlated with pathological and clinical status. A significant correlation was observed between reduced Fhit expression and advanced stage of the tumors. Overall, 26 of 30 (87%) primary TCCs showed abnormal transcripts. Fhit protein was absent or greatly reduced in 61% of the TCCs analyzed by immunohistochemistry. These results suggested that loss of Fhit expression may be as important in the development of bladder cancer as it is for other neoplasms caused by environmental carcinogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.